Europe AAV Gene Therapy Market Industry Trends and Forecast to 2034: Segmented by (Indication, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$687.0 MnPlaceholder estimate
Estimate 2025$815.5 Mn16.7% of the global market
Projected 2034$3.81 Bn 367.8%Adds $3.00 Bn over 9 forecast years
CAGR 2025–203418.7%Faster than 87% of 180 Pharmaceuticals markets here
23 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe AAV Gene Therapy Market Analysis Executive Summary
AAV gene therapies use harmless adeno-associated viruses to deliver working genes into cells, often as a one-time treatment.
Key segments of the AAV Gene Therapy market include indication (Neuromuscular Diseases, Hemophilia and Eye Diseases) and route (Intravenous, Subretinal and Intrathecal).
Europe AAV Gene Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe AAV Gene Therapy Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the AAV Gene Therapy market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the AAV Gene Therapy market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for AAV Gene Therapy Market in Europe
The AAV Gene Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for AAV Gene Therapy Market in Europe
AAV Gene Therapy in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8] ClinicalTrials.gov lists 23 studies on AAV Gene Therapy that are recruiting, active or about to start in Europe.[9]
[9]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AAV Gene Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Indication
4.2 By Route
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novartis
7.2 Sarepta Therapeutics
7.3 BioMarin
7.4 CSL Behring
7.5 Ultragenyx
7.6 REGENXBIO
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The AAV Gene Therapy market can be segmented based on various criteria, including indication, route and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in AAV Gene Therapy right now, from free public sources.
Clinical trials
23 active trials in UK, Germany, France, Italy, Spain and Russia
Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Placeholder estimate: about $815.5 Mn in 2025, rising to about $3.81 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the AAV Gene Therapy market in Europe growing?
Placeholder estimate: about 18.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the AAV Gene Therapy market report cover?
The report splits the market by indication (Neuromuscular Diseases, Hemophilia, Eye Diseases, Metabolic Disorders), route (Intravenous, Subretinal, Intrathecal) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the AAV Gene Therapy market?
Key players include Novartis AG, Sarepta Therapeutics, BioMarin, CSL Behring, Ultragenyx and REGENXBIO.
What is driving the AAV Gene Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.
Who regulates AAV Gene Therapy in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on AAV Gene Therapy are running in Europe?
23 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on AAV Gene Therapy?
PubMed lists 448 papers on AAV Gene Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
France
Brazil
UK
Italy
Ecuador
India
Spain
Saudi Arabia
Mexico
Russia
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya